share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP:信函
美股sec公告 ·  05/21 13:05
Moomoo AI 已提取核心訊息
NeuroSense Therapeutics Ltd., a biopharmaceutical company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company, based in Herzliya, Israel, seeks to have the registration become effective on May 22, 2024, at 4:00 p.m. Eastern Time. This request was made under Rule 461 of the Securities Act of 1933, as amended. NeuroSense Therapeutics has authorized its counsel, Greenberg Traurig, P.A., and specifically Gary Emmanuel, to communicate with the SEC regarding the effectiveness of the Registration Statement and to modify or withdraw the request for acceleration if necessary.
NeuroSense Therapeutics Ltd., a biopharmaceutical company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company, based in Herzliya, Israel, seeks to have the registration become effective on May 22, 2024, at 4:00 p.m. Eastern Time. This request was made under Rule 461 of the Securities Act of 1933, as amended. NeuroSense Therapeutics has authorized its counsel, Greenberg Traurig, P.A., and specifically Gary Emmanuel, to communicate with the SEC regarding the effectiveness of the Registration Statement and to modify or withdraw the request for acceleration if necessary.
神經感知治療有限公司(NeuroSense Therapeutics Ltd.)是一家生物製藥公司,正式要求證券交易委員會(SEC)加快其F-1表格的註冊聲明有效性。該公司位於以色列赫爾茲利亞,希望在2024年5月22日美國東部時間下午4:00左右,該註冊聲明生效。該要求是根據1933年修正的證券法案的規則461作出的。 NeuroSense Therapeutics已授權其律師Greenberg Traurig,PA以及特別是Gary Emmanuel與SEC就註冊聲明的有效性進行溝通,並在必要時修改或撤回加速要求。
神經感知治療有限公司(NeuroSense Therapeutics Ltd.)是一家生物製藥公司,正式要求證券交易委員會(SEC)加快其F-1表格的註冊聲明有效性。該公司位於以色列赫爾茲利亞,希望在2024年5月22日美國東部時間下午4:00左右,該註冊聲明生效。該要求是根據1933年修正的證券法案的規則461作出的。 NeuroSense Therapeutics已授權其律師Greenberg Traurig,PA以及特別是Gary Emmanuel與SEC就註冊聲明的有效性進行溝通,並在必要時修改或撤回加速要求。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息